IHE:NYE-iShares U.S. Pharmaceuticals ETF (USD)

ETF | Health |

Last Closing

USD 68.14

Change

+0.26 (+0.38)%

Market Cap

N/A

Volume

0.05M

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-04-30 )

Largest Industry Peers for Health

Symbol Name Price(Change) Market Cap
XLV Health Care Select Sector SPDR..

+1.19 (+0.85%)

USD 35.08B
FHLC Fidelity® MSCI Health Care In..

+0.46 (+0.70%)

USD 2.50B
FXH First Trust Health Care AlphaD..

+0.56 (+0.56%)

USD 0.89B
XHE SPDR® S&P Health Care Equipme..

-0.93 (-1.17%)

USD 0.16B
IDNA iShares Genomics Immunology an..

+0.28 (+1.35%)

USD 0.10B
XHS SPDR® S&P Health Care Service..

-0.36 (-0.37%)

USD 0.09B
SBIO ALPS Medical Breakthroughs ETF

+0.48 (+1.64%)

USD 0.08B
HTEC Robo Global® Healthcare Techn..

-0.03 (-0.11%)

USD 0.04B
BBP Virtus LifeSci Biotech Product..

+0.97 (+1.67%)

USD 0.02B
BBC Virtus LifeSci Biotech Clinica..

+0.40 (+2.14%)

USD 0.01B

ETFs Containing IHE

N/A

Market Performance

  Market Performance vs. Industry/Classification (Health) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 3.68% 86% B+ 80% B-
Dividend Return N/A N/A N/A N/A N/A
Total Return 3.68% 86% B+ 78% C+
Trailing 12 Months  
Capital Gain 4.78% 81% B- 60% D-
Dividend Return 1.00% 88% B+ 20% F
Total Return 5.79% 81% B- 51% F
Trailing 5 Years  
Capital Gain 37.31% 67% D+ 51% F
Dividend Return 9.14% 95% A 20% F
Total Return 46.46% 76% C+ 43% F
Average Annual (5 Year Horizon)  
Capital Gain 2.97% 62% D 47% F
Dividend Return 4.35% 67% D+ 44% F
Total Return 1.38% 100% F 33% F
Risk Return Profile  
Volatility (Standard Deviation) 14.35% 62% D 66% D+
Risk Adjusted Return 30.33% 67% D+ 47% F
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior total returns

The stock has outperformed its sector peers on average annual total returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile.

What to not like:

There is nothing we particularly dislike